

August 12, 2026

BSE Limited

Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd

Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Appointment of Directors - Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, this is to inform you that the following changes in the composition of the Board of Directors of the Company have been effected at the meeting of the Board held on **August 12, 2026**, based on the recommendation of the Nomination and Remuneration Committee:

1. Approved the re-appointment of Dr. Sridhar Ganesan (DIN: 06819026) as the Managing Director of the Company for a further period of two (2) years, with effect from August 25, 2026, to August 24, 2028, subject to the approval of the Shareholders at the ensuing AGM.
2. Approved the appointment of Mr. D. Muralidharan (DIN: 08301904) as the Whole-Time Director of the Company for a period of two (2) years, with effect from August 12, 2026, to August 11, 2028, subject to the approval of Shareholders at the ensuing AGM. Mr. Muralidharan shall continue as the Chief Financial Officer of the Company in addition to him being designated the Whole Time Director.

The details of the above Directors, in accordance with Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as **"Annexure- A"**.

Kindly take the same on your records.

Sincerely Yours

For Caplin Point Laboratories Limited

Venkatram G

General Counsel & Company Secretary

Membership No. A23989

Encl: A/a

ANNEXURE – A

S. No	Particular	Dr. Sridhar Ganesan	Mr. D. Muralidharan
1	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-appointment of Dr. Sridhar Ganesan (DIN: 06819026) as the Managing Director of the Company	Appointment of Mr. D. Muralidharan (DIN: 08301904) as the Whole-Time Director of the Company
2	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	August 25, 2026	August 12, 2026
3	Brief profile	Dr. Sridhar Ganesan has over 35 years of global leadership experience in the pharmaceutical industry, with expertise spanning profit centre management, global marketing, international business development, project planning and implementation, production, new product development, quality assurance and factory management. He has held leadership positions across various international assignments, with extensive experience in South Asia, the Middle East and Africa. As Managing Director of the Company, he provides strategic leadership in driving the Company's growth and expanding its global footprint.	Mr. D. Muralidharan has been serving as the Chief Financial Officer (CFO) of the Company since February 19, 2016. He is a seasoned finance professional with rich academic credentials, holding a bachelor's degree in commerce (B. Com), Associate Membership of the Institute of Company Secretaries of India (ICSI), and Cost & Management Accountant qualification from Institute of Cost Accountants of India (ICMAI). He is also a member of the Risk Management Committee of the Company.
4	Disclosure of relationships between directors (in case of appointment of a director).	NIL	Nil



CAPLIN POINT®
Laboratories

Caplin Point Laboratories Limited

Regd. office: Ashvich Tower, 3rd Floor,

No.3, Developed Plots Industrial Estate, Perungudi, Chennai – 600096.

Phone : +91 44 24968000 / +91 80127 72888 / +91 44 71148000

E-mail : info@caplinpoint.net / Website : www.caplinpoint.net

CIN : L24231TN1990PLC019053

5	Information required pursuant to BSE Circular no. LIST/COMP/14/2018-19 and the NSE Circular no. NSE/CML/2018/24, both dated 20th June 2018	Dr. Sridhar Ganesan is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.	Mr. D. Muralidharan is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.
---	--	--	--